Pulmonary Fibrosis Reversal
Move from slowing lung scarring to reversing it
The goal is to reverse the scarring of pulmonary fibrosis — to unwind the stiff scar tissue that replaces healthy lung — so that breathing capacity is recovered, not just preserved a little longer.
In pulmonary fibrosis, healthy lung is slowly replaced by stiff scar tissue, and breathing becomes harder until it fails. Today’s approved medicines can slow that decline, but they do not halt or reverse the scarring — and the disease remains progressive and often fatal. The field is now shifting its aim from containment toward regenerative restoration. Reversing lung scarring would change the entire outlook. It is the restorative companion to alveolar regeneration.
We are building the capability to unwind lung fibrosis and restore breathing: stopping the scarring process, breaking down and clearing scar that has already formed, and regenerating functional lung tissue in its place.
From containment to regeneration
Slowing the scarring Clinical
Approved antifibrotic medicines slow the decline in lung function — meaningful but bounded benefit, and the current standard of care.
Reversing established scar Frontier
New agents in trials aim to break down and reverse existing fibrosis rather than only slow it — early and not yet proven in people.
Regenerating lung tissue Frontier
Stem-cell and regenerative approaches aim to rebuild functional lung where scar has formed — shared with alveolar regeneration.
Clearing the cells that scar Frontier
Senolytic and targeted approaches aim to remove the cells driving fibrosis, studied in early trials.
Cited as evidence the capability is real — not as partners or endorsers.
Universities & institutes
Academic pulmonary, lung-regeneration, and fibrosis research centers (and patient-research foundations) developing antifibrotic and regenerative therapies.
Government & programs
National Heart, Lung, and Blood Institute (NHLBI, NIH) · NIH lung- and regenerative-medicine programs.
Enabling science base
antifibrotic therapeutics · fibrosis biology · lung stem cells · senolytics · single-cell lung mapping.
The technologies: approved antifibrotics that slow decline; next-generation antifibrotics in trials aiming to reverse scar; lung stem-cell and regenerative approaches to rebuild tissue; senolytics to clear scarring cells; and single-cell lung mapping that is reframing fibrosis as a dynamic, treatable process rather than a fixed scar.
Antifibrotics slow decline Clinical
Approved antifibrotic drugs reduce the rate of lung-function decline — real but bounded benefit; they do not reverse scarring.
Reversal agents in trials Frontier
Newer agents designed to reverse fibrosis are in clinical trials, with some under regulatory review for slowing decline — reversal not yet established.
Regenerative approaches Frontier
Stem-cell and exosome approaches to rebuild lung tissue show early promise in research.
Senolytics in early studies Frontier
Clearing scarring-driver cells is being tested in early trials.
The honest challenges, stated plainly: no approved therapy yet reverses established lung scarring or restores lost lung architecture — today’s drugs slow decline. Reversal agents are early and unproven in people. Rebuilding the lung’s intricate gas-exchange structure is genuinely hard. What is real and clinical: slowing the decline. What is frontier: true reversal and regeneration. We will not blur that line.
The future, fully built
A person with pulmonary fibrosis — losing breath as scar spreads — has the scarring unwound: the process stopped, existing scar cleared, functional lung regenerated, breathing recovered rather than only preserved. Lung scarring becomes something we reverse, not merely slow.
The proof, for this capability
Cited as evidence the capability is real, not as partners or endorsers.
Approved antifibrotics
Approved drugs slow the rate of lung-function decline; they do not reverse scarring. Stage: Clinical (slowing).
Reversal agents in trials
Next-generation agents aiming to reverse fibrosis are in clinical trials, some under review for slowing decline; reversal not yet established. Stage: Frontier.
Regenerative & senolytic approaches
Stem-cell, exosome, and senolytic approaches to rebuild lung and clear scarring cells are in early research. Stage: Frontier.
Honest framing
Real organizations and studies are cited as evidence the capability is real — not as partners or endorsers. No approved therapy reverses established lung scarring; nothing here claims one does.
Help build this future
Every signature grows the movement to make lung-fibrosis reversal real — and free at the point of need.